San Diego-based Viking Therapeutics marked itself as a serious competitor while in the weight loss drug industry in February soon after revealing promising data from a mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection As well as in March the co